The decision of federal officials to allow pharmacies to produce unapproved versions of KV Pharmaceutical's preterm birth drug Makena is getting another look after a meningitis outbreak tied to another pharmacy-made treatment. Many state and private sector insurance officials restrict or discourage the use of Makena in favor of less-expensive pharmacy-made versions.